Abstract
Type 2 diabetes mellitus(T2DM) as a common chronic disease with an increasing prevalence worldwide that poses a great threat to individual health, and is characterized by chronic hyperglycemia resulting from insulin resistance (IR) coupled with β-cell dysfunction. Mitochondrial dysfunction, obesity, gut microbiota, oxidative stress and inflammation have emerged as a significant contributor to the etiology of T2DM, affecting various metabolic processes critical for glucose homeostasis. This short review underscores their role in enhancing T2DM-related molecular mechanisms and explores recent advancements in diabetic management, further highlights the importance of personalized care plans to address the complexities of the T2DM and aims to improve patient quality of life and long-term health outcome.
1 Introduction
Type 2 diabetes mellitus (T2DM) is a renowned overgrowing endocrine metabolic disease, and occurs as a result of insulin resistance (IR) and inadequate insulin production, resulting in hyperglycemia, presenting a substantial burden on global healthcare systems (, ). IR is characterized by an impaired cellular response to insulin stimulation in peripheral tissues, such as the liver, skeletal muscle and adipose tissue.
As T2DM advances, progressive beta cell dysfunction occurs, results in relative insulin deficiency of insulin secretion (). Besides that, mitochondrial dysfunction, obesity, gut microbiota, oxidative stress and inflammation are also implicated in the etiology of T2DM,these different pathogenic factors underscore the urgent need for multifactorial approach that address not only control of hyperglycemia but also the broader implications and side-effects impact of overall health and well-being (). T2DM management, pharmacological interventions alone is insufficient, lifestyle modifications, weight management, regular physical activity and patient self-management are critical to advance diabetic care (). In fact, by addressing multifactorial characteristics of onset and development in T2DM, a focus on individualized care and prevent the risk of complications must consider patient-specific needs, effective and sustainable treatment preferences, comorbidities, ultimately optimizing patient overall quality of life and long-term health outcomes (). Lastly, we discuss the latest therapeutic innovations, like gene therapy, regenerative medicine and identification of omics-related biomarkers, aid in gaining a deeper comprehension of holistic care and precision medicine among diabetic patients.
2 Mechanisms and pathogenic factors of IR
2.1 Mitochondrial dysfunction
Mitochondria, commonly known as the “powerhouses” of cells, containing their own double-stranded DNA (mtDNA), which encodes 13 polypeptides constitute mostly part of the electron transfer chain (ETC) (). In fact, the mitochondrial ETC is the site of oxidative phosphorylation (OXPHOS), which is key in glucose metabolism and the biggest net producer of ATP in mammalian cells (). Mitochondria play a crucial role in apoptosis, signaling, oxidation processes, and cellular energy consumption and balance, as well as are vital for the proper functioning and survival of pancreatic β-cells (). When mitochondria are dysfunctional, uncontrolled fission or fusion occurs, like impaired mitochondrial fusion or excessive mitochondrial fission, resulting in impaired mitochondrial dynamics and mitochondrial fragmentation. Reactive oxygen species (ROS) are next to the location of the mtDNA and produced by OXPHOS, this makes the mtDNA highly susceptible to oxidative damage, thus increasing the probability of mutations and further disturbing mitochondrial energy metabolism (, ). Meanwhile, this oxidative damage compromises mETC function and worsens energy failure, in addition to oxidative stress and dysfunctional mitochondria, which have been implicated in the part pathogenesis of various diseases, including DM (). Peroxisome proliferator-activated receptors (PPARs) agonists, like pioglitazone is a promising thiazolidinediones and restores mitochondrial function in patients with T2DM (13). Glimins represent a new class of oral glucose-lowering drugs, primarily targeting the mitochondrial respiratory chain complex to reduce the production of ROS and prevent mitochondrial meability transition pore opening, thereby restoring mitochondrial function in skeletal muscle, liver, and pancreas of diabetic patients (14, 15).
2.2 Mitochondrial biogenesis
Mitochondrial biogenesis is implicated in cells grow and mitochondrial responses to environmental cues and metabolic demands, which is a key feature of mitochondrial function, its dysregulation contributes to the development and progression of T2DM (16). Transcriptional coactivators peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), initiates mitochondrial biogenesis pathway by sequential activations of nuclear transcription factors, including nuclear respiratory factors (NRF1/2), estrogen-related receptor-alpha(ERR-α), followed by mitochondrial transcription factor A (TFAM) and mtDNA replication and transcription. Dysregulation of PGC-1α activity leads to impaired mitochondrial biogenesis and gene expression in oxidative phosphorylation and metabolic disorders (17). Sirtuin 1 (Sirt1) is a nicotinamide adenine dinucleotide (NAD+) -dependent histone deacetylase that plays a significant role in modulating PGC-1α activity, promoting mitochondrial biogenesis and renewal (18). Inflammatory cytokines, calcium (Ca2+) regulation and metabolic stressors, such as hyperglycaemia and dyslipidaemia, are also linked to inhibit mitochondrial biogenesis and promote onset of IR (19). Substances such as 5-Aminoimidazole-4-carboxamide ribotide, GW501516, and various natural compounds present in epicatechin, have been identified as potential pharmacological via stress kinases, transcription factors and peroxisome proliferator-activated receptors (PPARs) activation, as well as mitochondrial function restoration to alleviate metabolic abnormalities (20). Besides, mitochondrial gene therapy has emerged as an innovative tool hold significant promise for restoring mitochondrial function and enhancing cellular bioenergetics (21). Addressing mitochondrial dysfunction and T2DM crosstalk is crucial for understanding the biochemistry mechanisms involved in overproduction of ROS, reduced ATP synthesis, dysregulated mitochondrial dynamics, poor mitochondrial biogenesis, and impaired mitochondrial gene expression, resulting in imbalance between energy generation and consumption, further exacerbate metabolic disorders, which may be exactly identified the relationship between mitochondrial dysfunction and molecular mechanisms underlying T2DM is multifaceted and complex (16)(Figures 1a, b).
Figure 1
2.3 Obesity
An long-term imbalance in energy between intake and expenditure is a key characteristic of individuals with obesity, and then chronic exposure to hyperglycemia, dyslipidemia, glucotoxicity impairs β-cell function and viability, leading to progressive deterioration of insulin secretion capacity (22, 23). Brown adipose tissue (BAT) is a distinct type of adipose tissue that dissipates energy and plays a natural anti-obesity role. White adipose tissue (WAT) primarily stores energy. Disturbances in BAT and WAT homeostasis have been associated with certain microbial imbalances and onset of obesity (24). Given that obesity has been closely implicated in the pathogenesis of T2DM (Figure 1c). Browning agents, such as cold exposure, β-3 adrenergic receptor agonists (CL 316243, BRL 26830A), short-chain fatty acids (butyrate, propionate, acetate), are compounds that can promote the conversion of WAT into BAT, may hold promise as a target for treating and preventing T2DM (25, 26). Besides, as reciprocal causation between obesity and T2DM, significant progress in the pharmacological treatment revolve around insulin resistance-mediated obesity. Metformin is the preferred first line antidiabetic drug, exerts its therapeutic effects by increasing insulin sensitivity, glucose uptake by activating adenosine monophosphate activated protein kinase, promoting weight loss, improving lipid profiles, as well as modulating mitochondrial dynamics and biogenesis, thus contributing to its metabolic benefits in T2DM onset (27). Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as dapagliffozin and empagliffozin, have emerged as promising therapeutic agents for antihyperglycemic management (28). These substances reduce body weight, initially through a direct effect, and subsequently by shifting substrate utilization from carbohydrates to lipids, thereby reducing body fat, including visceral and subcutaneous fat (29, 30). Gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted by cells in the human gut after food intake and regulate insulin release by pancreatic β-cells, and involved in blood sugar homeostasis. Tirzepatide acts on the GIPR/GLP-1R receptors, and is a recently developed drug useful in the treatment of T2DM and for weight loss, studies show its role in improving circulating levels of adiponectin, eventually influences lipid and glucose metabolism (31, 32). What needs to be emphasized that each drug has specific mechanisms and potential side effects, necessitating the significance of personalized treatment plan. Besides that, bariatric surgery like sleeve gastrectomy, one-anastomosis gastric bypass, and Roux-en-Y gastric bypass have the potential to induce remission of T2DM-related obesity (33).
2.4 Gut microbiota
The human gut microbiome is a complex ecosystem, composed of bacteria, archaea, fungi, viruses and protozoa in the human intestinal tract, which participate in material and energy metabolism, each exerting a unique influence on host metabolism (34, 35). In the context of T2DM, the gut microbiome exhibits notable changes, termed dysbiosis, which is closely related with dysregulation of a host metabolism, where there is an increase in bacteria that negatively impact metabolic health and a decrease in beneficial bacteria (36, 37). Bacteroides uniformis and Bacteroides acidifaciens can negatively improve glucose tolerance and insulin sensitivity, and are instrumental in managing T2DM, Faecalibacterium, Akkermansia, and Roseburia also exhibit similar negative correlations with the metabolic diseases (38, 39). Therefore, diabetic patients often exhibit an increase in harmful bacteria, such as Escherichia and Prevotella, Iatcu OC (40). Short-chain amino acids (SCFAs),like butyrate, propionate and acetate regulate pancreatic beta-cell activity, reduce hepatic gluconeogenesis, and modulate immune system functions (41). Moreover, the alternation of branched-chain amino acids (BCAAs) increases liver gluconeogenesis and inhibits liver adipogenesis, directly contributes to the pathogenesis of T2DM (42, 43). Notably, the changes in gut microbiota are related to LPS-induced inflammatory responses, exacerbating IR in T2DM,further emphasizing microbiome’s role in glucose homeostasis and immune response (44) (Figure 2a). This emerging field offers diverse applications, particularly in modifying the gut environment through the administration of probiotics, including Bifidobacterium (adolescentis, animalis, bifidum, reuteri, breve, longum)and Lactobacillus (acidophilus, casei, fermentum, gasseri, johnsonii, paracasei, plantarum, rhamnosus, and salivarius) can potentially alleviate or even reverse the metabolic dysfunctions associated with T2DM (45). Additionally, diabetic medications Alpha-glucosidase inhibitors promote the growth of beneficial microbes such as Bacteroides, Lactobacillus, and Faecalibacterium, while reducing populations of potentially pathogenic bacteria like Ruminococcus and Butyricicoccus (46). GLP-1 agonists also promote the growth of SCFA-producing bacteria such as Bifidobacterium and Bacteroides, further supporting glycemic control and metabolic health (47). Sodium-glucose co-transporter type 2 inhibitors, such as sotagliflozin, impact the gut microbiome by decreasing the Firmicutes/Bacteroides ratio and enhancing fatty acid production (48). Spermidine can significantly change the composition and function of intestinal microbiota, moderately reduce the level of circulating LPS, improve metabolic endotoxemia, weaken cell apoptosis to enhance intestinal barrier function (49). Fecal microbiota transplantation (FMT) effectively mitigates damage to the intestinal barrier through altering the microbial structure (50).
Figure 2
2.5 Inflammation
T2DM patients have elevated blood glucose and free fatty acids levels, dyslipidemia, impaired insulin receptor function. Metabolic inflammation is one of markedly causatives among the metabolic derangement factors (51). Specifically, chronic hyperglycemia and hyperlipidemia are the typical features of diabetes manifestations, which inevitably lead to glucolipotoxicity and in turn alter mitochondrial function. Dysfunctional mitochondria induce non-physiological generation of ROS, exacerbate the disturbance of inflammatory microenvironmental balance between adipose and pancreatic islet tissue, inevitably forming a vicious cycle (52, 53). Along with chronic production of proinflammatory cytokines and inefficient fatty acid β-oxidation, triggering a decrease in β cell insulin secretion and an increase in IR. Chronic overload of free fatty acids and glucose trigger inflammatory pathways (AMPK and PPARγ) directly or via increased production of ROS, which is the possible causative factor in the metabolic inflammation (54, 55),depicted in Figure 2b. Adipose tissue-derived cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), promote IR by interfering with insulin signaling pathway and promoting inflammation (56). The anti-inflammatory mediators, such as visfatin, plasminogen activator inhibitor-1, blocking IL-1R,anti-IL-1β,anti-TNF-α,CCR2 antagonists and IL-6R inhibitors, have emerged as available therapeutic approach for reversing T2DM (57).
2.6 Oxidative stress
Reactive oxygen species(ROS) are byproducts of mitochondrial metabolism, as hyperglycemia advances, oxidative stress in β-cells is often driven by mitochondrial ROS, which overwhelms the body’s antioxidant defenses, leading to impairment of insulin signaling pathway and metabolic dysregulation, thus plays a significant role in the pathophysiology of T2DM and its associated complications causing IR (58, 59). Most antioxidants, like SS-31 (elamipretide) and SkQ1,that reduces oxidative stress and maintains mitochondrial function offer a potential treatment strategy for T2DM and its complications (60). Additionally, ROS-mediated oxidative stress activates stress kinases and pro-inflammatory pathways, such as nuclear factor κB (NF-κB),which stimulates the release of proinflammatory cytokines and further exacerbating β-cell dysfunction and IR () (Figure 2c). Quercetin, curcumin, resveratrol, vitamin C and vitamin D have emerged as critical mediators in this antioxidant process, linking nuclear factor erythroid 2-related factor 2 (Nrf2) pathway and inflammation signaling to counteract β-cell dysfunction in diabetes (61). Glutathione (GSH), a water-soluble antioxidant, plays a critical role in maintaining cellular homeostasis and mitigating oxidative stress, study shows that metformin, teneligliptin, and pioglitazone not only impacts GSH redox pathway but also preserves β-cell function (62, 63). Therapeutic strategies focusing on reducing oxidative stress, enhancing antioxidant defenses, and focusing on Mediterranean diet, such as vegetables, function and preventing diabetes progression (64). It becomes increasingly evident that therapeutic strategies focusing on targeting oxidative stress pathways and enhancing antioxidant defenses as promising therapeutic strategies to preserve β-cell function and prevent diabetic progression.
3 Conclusion and perspective
Type 2 diabetes mellitus stands as the most prevalent metabolic disease globally, characterized by intricate pathophysiological mechanism, including IR, impaired glucose homeostasis and β-cell dysfunction, genetic and environmental variables are also implicated in the etiology of T2DM. Considering multifactorial contributors of diabetes, such as mitochondrial dysfunction, obesity and gut microbiota, mutually reinforcing each other, and creating a vicious cycle that exacerbates both insulin sensitivity and resistance, underscores the urgent need for effective T2DM management strategies that not only offer improved hypoglycemic control but also address the broader health implications (). Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors, distinguishes itself for its favorable glycemic control ability and its broader effects such as increasing insulin secretion, improving glucose homeostasis, and refining appetite modulation, clinical trials have demonstrated significant reductions in body weight superior to dulaglutide, tirzepatide, and even semaglutide (65–67). Dorzagliatin and Cadisegliatin are promising antidiabetic drugs activate Glucokinase (GK), which regulate glucose metabolism and enhance beta cell function in diabetic patients, although they are still in the clinical stages (68, 69).
As diabetes management continues to advance, regenerative medicine has evolved significantly, with modern therapeutic avenues and a broader focus on immunomodulatory properties and adjuvant delivery biomaterials to repair damaged tissues, like mesenchymal stem cells (70). Immune cell-derived exosomes (including engineered exosomes) may also regulate the function of immune cells by transferring miRNA and mRNA, making them a promising directions reverse metabolic disorders of T2DM (71). Although they have great clinical application prospects, there are associated hurdles about immune rejection, tumorigenesis and the precise manipulation of stem cell behaviors needed to be surmounted (70). Gene therapy differs from a glucocentric approach, utilizes lentivirus, adenovirus, adeno-associated virus (AAV), along with non-viral techniques like liposomes and naked DNA, to deliver the insulin gene to target tissues, such as CRISPR-Cas9 sequencing enables to precise modification mtDNA mutations associated with T2DM, offering potential therapeutic precision and safety for metabolic disorders (72, 73).
Omic-related fields have illuminated a path of immense promise and significant potential for revolutionizing modern therapeutic interventions. Insist hyperglycemia impacts the metabolism of glucose, lipids, amino acids, as well as gut microbiota, which all in turn impact the drug responses of individuals living with T2DM.Hence, metabolomics, lipidomics and microbiomics are applied to uncover additional biomarkers that might better predict heterogeneity observed in personalized management outcome and enhance our understanding of disease mechanisms, thus offering new opportunities for various diabetic stages and patient-specific therapeutic interventions (74). Additionally, with the complex nature of T2DM and its widespread prevalence, the integration of precision medicine into all-around care should consider a myriad of factors encompass social, demographics, phenotypic, biochemical, genetic aspects, and individual patient variability (75). Complementary and alternative medicine (CAM) therapies herbal remedies like cinnamon, fenugreek, and bitter melon, allied with mindbody therapies, including yoga, tai chi, and meditation offers holistic and patient-centered approach to alleviate disease progression, have been viewed as complementary strategy to advance T2DM care ().Moreover, interdisciplinary research is the foreword trend to develop diabetic treatment, artificial intelligence (AI) technologies analyze genes, proteins and metabolites, provide more intelligent and precise support from early screening, diagnosis to personalized treatment and monitoring, and leveraging machine learning algorithms to assess the risk trend in metabolic diseases and empower patients in self-management (76, 77). While AI has opened new options for conquering complexity of the human insulin system, sole reliance on it for personalized treatment is far from enough, it still needs collaboration with healthcare professionals, researchers, and technical implementation experts to harness the full potential of AI in diabetic management (78).
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.
Author contributions
LW: Writing – original draft. LL: Resources, Writing – review & editing. JL: Methodology, Writing – review & editing. MY: Validation, Writing – review & editing. ZH: Writing – review & editing. CS: Writing – review & editing, Investigation. RY: Investigation, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by Natural Science Foundation of Sichuan province (No. 23NSFC6268), Science and Technology Planning Project of sichuan province (No. 2023YFS0329), National Natural Science Foundation of China (No.82305209).
Acknowledgments
We gratefully acknowledge the teachers of the Hospital of Chengdu University of Traditional Chinese Medicine for their strong support in this study, as well as the encouraging words given by the leaders of the hospital.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
CaturanoAD’AngeloMMormoneARussoVMollicaMPSalvatoreTet al. Oxidative stress in type 2 diabetes: impacts from pathogenesis to lifestyle modifications. Curr Issues Mol Biol. (2023) 45:6651–66. doi: 10.3390/cimb45080420
2
McBenedictBOrfaoALGohKSYauRCCAlphonseBMachado LimaJet al. The role of alternative medicine in managing type 2 diabetes: A comprehensive review. Cureus. (2024) 16:e61965. doi: 10.7759/cureus.61965
3
CannonAHandelsmanYHeileMShannonM. Burden of illness in type 2 diabetes mellitus. J Manag Care Spec Pharm. (2018) 24:S5–S13. doi: 10.18553/jmcp.2018.24.9-a.s5
4
MarxNFedericiMSchüttKMüller-WielandDAjjanRAAntunesMJet al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. (2023) 44:4043–140. doi: 10.1093/eurheartj/ehad192
5
CaturanoAGalieroRRoccoMTagliaferriGPiacevoleANiloDet al. Modern challenges in type 2 diabetes: balancing new medications with multifactorial care. Biomedicines. (2024) 12:2039. doi: 10.3390/biomedicines12092039
6
VicenteAMBallensiefenWJönssonJI. How personalised medicine will transform healthcare by 2030: the ICPerMed vision. J Transl Med. (2020) 18:180. doi: 10.1186/s12967-020-02316-w
7
AndersonSBankierATBarrellBGde BruijnMHCoulsonARDrouinJet al. Sequence and organization of the human mitochondrial genome. Nature. (1981) 290:457–65. doi: 10.1038/290457a0
8
Nolfi-DoneganDBraganzaAShivaS. Mitochondrial electron transport chain: Oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol. (2020) 37:101674. doi: 10.1016/j.redox.2020.101674
9
LuoJSNingJQChenZYLiWJZhouRLYanRYet al. The role of mitochondrial quality control in cognitive dysfunction in diabetes. Neurochem Res. (2022) 47:2158–72. doi: 10.1007/s11064-022-03631-y
10
MartinezJMarmisolleITaralloDQuijanoC. Mitochondrial bioenergetics and dynamics in secretion processes. Front Endocrinol. (2020) 11:319. doi: 10.3389/fendo.2020.00319
11
ThubronEBRosaHSHodgesASivaprasadSFrancisPTPienaarISet al. Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer’s disease are not present in diabetic Alzheimer’s disease. Sci Rep. (2019) 9:11386. doi: 10.1038/s41598-019-47783-4
12
YangLHanWLuoYHuXXuYLiHet al. Adapentpronitrile, a new dipeptidyl peptidase-IV inhibitor, ameliorates diabetic neuronal injury through inhibiting mitochondria-related oxidative stress and apoptosis. Front Cell Neurosci. (2018) 12:214. doi: 10.3389/fncel
13
IpsenEØMadsenKSChiYPedersen-BjergaardURichterBMetzendorfMIet al. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. (2020) 11:CD013516. doi: 10.1002/14651858.CD013516.pub2
14
Hallakou-BozecSVialGKergoatMFouquerayPBolzeSBorelALet al. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes. Diabetes Obes Metab. (2021) 23:664–73. doi: 10.1111/dom
15
DetailleDVialGBorelALCottet-RouselleCHallakou-BozecSBolzeSet al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. (2016) 2:15072. doi: 10.1038/cddiscovery.2015.72
16
SultanaMAHiaRAAkinsikuOHegdeV. Peripheral mitochondrial dysfunction: A potential contributor to the development of metabolic disorders and alzheimer’s disease. Biol (Basel). (2023) 12:1019. doi: 10.3390/biology12071019
17
Rius-PérezSTorres-CuevasIMillánIOrtegaÁLPérezS. PGC-1α, inflammation, and oxidative stress: an integrative view in metabolism. Oxid Med Cell Longev. (2020) 2020:1452696. doi: 10.1155/2020/1452696
18
TangBL. Sirt1 and the mitochondria. Mol Cells. (2016) 39:87–95. doi: 10.14348/molcells.2016.2318
19
Galicia-GarciaUBenito-VicenteAJebariSLarrea-SebalASiddiqiHUribeKBet al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. (2020) 21:6275. doi: 10.3390/ijms21176275
20
GolubitzkyADanPWeissmanSLinkGWikstromJDSaadaA. Screening for active small molecules in mitochondrial complex I deficient patient’s fibroblasts, reveals AICAR as the most beneficial compound. PloS One. (2011) 6:e26883. doi: 10.1371/journal.pone.0026883
21
RussellOMGormanGSLightowlersRNTurnbullDM. Mitochondrial diseases: hope for the future. Cell. (2020) 181:168–88. doi: 10.1016/j.cell.2020.02.051
22
SzűcsGPipiczMSzabóMRCsontTTörökLCsonkaC. Effect of eccentric exercise on metabolic health in diabetes and obesity. Sports Med Open. (2023) 9:91. doi: 10.1186/s40798-023-00596-2
23
NussbaumerovaBRosolovaH. Obesity and dyslipidemia. Curr Atheroscler Rep. (2023) 25:947–55. doi: 10.1007/s11883-023-01167-2
24
XuJQJiangMXXuYJDongSJ. Research progress in the regulation of functional homeostasis of adipose tissue by exosomal miRNA. Sheng Li Xue Bao. (2024) 76:791–800.
25
WankhadeUDShenMYadavHThakaliKM. Novel browning agents, mechanisms, and therapeutic potentials of brown adipose tissue. BioMed Res Int. (2016) 2016:2365609. doi: 10.1155/2016/2365609
26
GhesmatiZRashidMFayeziSGieselerFAlizadehEDarabiM. An update on the secretory functions of brown, white, and beige adipose tissue: Towards therapeutic applications. Rev Endocr Metab Disord. (2024) 25:279–308. doi: 10.1007/s11154-023-09850-0
27
de MarañónAMDíaz-PozoPCanetFDíaz-MoralesNAbad-JiménezZLópez-DomènechSet al. Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients. Redox Biol. (2022) 53:102342. doi: 10.1016/j.redox.2022.102342
28
FatimaARasoolSDeviSTalhaMWaqarFNasirMet al. Exploring the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors: expanding horizons beyond diabetes management. Cureus. (2023) 15:e46243. doi: 10.7759/cureus.46243
29
TomitaIKumeSSugaharaSOsawaNYamaharaKYasuda-YamaharaMet al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. (2020) 32:404–419.e6. doi: 10.1016/j.cmet.2020.06.020
30
CaiXYangWGaoX. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: A meta-analysis. Obesity. (2018) 26:70–80:et al. doi: 10.1002/oby.22066
31
ThomasMKNikooienejadABrayRCuiXWilsonJDuffinKet al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. (2021) 106:388–96. doi: 10.1210/clinem/dgaa863
32
ZimmermannTThomasLBaader-PaglerTHaebelPSimonEReindlWet al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. (2022) 66:101633. doi: 10.1016/j.molmet.2022.101633
33
KermansaraviMChiappettaSKassirRBoscoAGiudicelliXLainasPet al. Efficacy of one anastomosis gastric bypass versus sleeve gastrectomy and roux-en-Y gastric bypass for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Obes Surg. (2024) 34:4555–62. doi: 10.1007/s11695-024-07564-z
34
WangRTangRLiBMaXSchnablBTilgH. Gut microbiome, liver immunology, and liver diseases. Cell Mol Immunol. (2021) 18:4–17. doi: 10.1038/s41423-020-00592-6
35
ZhouZSunBYuDZhuC. Gut microbiota: an important player in type 2 diabetes mellitus. Front Cell Infect Microbiol. (2022) 12:834485. doi: 10.3389/fcimb.2022.834485
36
MercerKYeruvaLPackLGrahamJLStanhopeKLChintapalliSVet al. Xenometabolite signatures in the UC davis type 2 diabetes mellitus rat model revealed using a metabolomics platform enriched with microbe-derived metabolites. American journal of physiology. Gastrointest. Liver. Physiol. (2020) 319:G157–69. doi: 10.1152/ajpgi.00105.2020
37
NoureldeinMBitarSYoussefNAzarSEidAA. Butyrate modulates diabetes-linked gut dysbiosis: epigenetic and mechanistic modifications. J Mol Endocrinol. (2020) 64:29–42. doi: 10.1530/jme-19-0132
38
YangJYLeeYSKimYLeeSHRyuSFukudaSet al. Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice. Mucosal Immunol. (2017) 10:104–16. doi: 10.1038/mi.2016.42
39
ZhangXShenDFangZJieZQiuXZhangCet al. Human gut microbiota changes reveal the progression of glucose intolerance. PloS One. (2013) 8:e71108. doi: 10.1371/journal.pone.0071108
40
HamamahSCovasaM. Harnessing prebiotics to improve type 2 diabetes outcomes. Nutrients. (2024) 16:3447. doi: 10.3390/nu16203447
41
JeyaramanMMariappanTJeyaramanNMuthuSRamasubramanianSSantosGSet al. Gut microbiome: A revolution in type II diabetes mellitus. World J Diabetes. (2024) 15:1874–88. doi: 10.4239/wjd.v15.i9.1874
42
VanweertFde LigtMHoeksJHesselinkMKCSchrauwenPPhielixEet al. Elevated plasma branched-chain amino acid levels correlate with type 2 diabetes-related metabolic disturbances. J Clin Endocrinol Metab. (2021) 106:e1827–1836:et al. doi: 10.1210/clinem/dgaa751
43
ZhaoHZhangFSunDWangXZhangXZhangJet al. Branched-chain amino acids exacerbate obesity-related hepatic glucose and lipid metabolic disorders via attenuating akt2 signaling. Diabetes. (2020) 69:1164–77. doi: 10.2337/db19-0920
44
FangYZhangCShiHWeiWShangJZhengRet al. Characteristics of the gut microbiota and metabolism in patients with latent autoimmune diabetes in adults: A case-control study. Diabetes Care. (2021) 44:2738–46. doi: 10.2337/dc20-2975
45
RittiphairojTPongpirulKJanchotKMuellerNTLiT. Probiotics contribute to glycemic control in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Adv Nutr. (2021) 12:722–34. doi: 10.1093/advances/nmaa133
46
ZhangXFangZZhangCXiaHJieZHanXet al. Effects of acarbose on the gut microbiota of prediabetic patients: A randomized, double-blind, controlled crossover trial. Diabetes Ther. (2017) 8:293–307. doi: 10.1007/s13300-017-0226-y
47
ZhangQXiaoXZhengJLiMYuMPingFet al. Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats. Exp Biol Med. (2018) 243:34–44. doi: 10.1177/1535370217743765
48
CefaloCMACintiFMoffaSImprontaFSoriceGPMezzaTet al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. (2019) 18:20. doi: 10.1186/s12933-019-0828-y
49
EisenbergTKnauerHSchauerABüttnerSRuckenstuhlCCarmona-GutierrezDet al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol. (2009) 11:1305–14. doi: 10.1038/ncb1975
50
ChengSMaXGengSJiangXLiYHuLet al. Fecal microbiota transplantation beneficially regulates intestinal mucosal autophagy and alleviates gut barrier injury. mSystems. (2018) 3:e00137–18. doi: 10.1128/mSystems.00137-18
51
ArabshomaliABazzazzadehganSMahdiFShariat-MadarZ. Potential benefits of antioxidant phytochemicals in type 2 diabetes. Molecules. (2023) 28:7209. doi: 10.3390/molecules28207209
52
TangvarasittichaiS. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. (2015) 6:456–80. doi: 10.4239/wjd.v6.i3.456
53
GaoZChenX. Fatty acid β-oxidation in kidney diseases: perspectives on pathophysiological mechanisms and therapeutic opportunities. Front.Pharmacol. (2022) 13:805281. doi: 10.3389/fphar.2022.805281
54
PawlakMLefebvrePStaelsB. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. (2015) 62:720–33. doi: 10.1016/j.jhep.2014.10.039
55
KeRXuQLiCLuoLHuangD. Mechanisms of AMPK in the maintenance of AT balance during energy metabolism. Cell Biol Int. (2018) 42:384–92. doi: 10.1002/cbin.10915
56
IheagwamFNBatihaGEOgunlanaOOChineduSN. Terminalia catappa extract palliates redox imbalance and inflammation in diabetic rats by upregulating nrf-2 gene. Int J Inflam. (2021) 2021:9778486. doi: 10.1155/2021/9778486
57
DakroubANasser SAYounisNBhaganiHAl-DhaheriYPintusGet al. Visfatin: A possible role in cardiovasculo-metabolic disorders cells. Cells. (2020) 9:2444. doi: 10.3390/cells9112444
58
SSHegdeSVAgarwalSVNsDPillaiAShahSNet al. Biomarkers of oxidative stress and their clinical relevance in type 2 diabetes mellitus patients: A systematic review. Cureus. (2024) 16:e66570. doi: 10.7759/cureus.66570
59
IheagwamFNIheagwamOTOnuohaMKOgunlanaOOChineduSN. Terminalia catappa aqueous leaf extract reverses insulin resistance, improves glucose transport and activates PI3K/AKT signalling in high fat/streptozotocin-induced diabetic rats. Sci Rep. (2022) 12:10711. doi: 10.1038/s41598-022-15114-9
60
MasonSAWadleyGDKeskeMAParkerL. Effect of mitochondrial-targeted antioxidants on glycaemic control, cardiovascular health, and oxidative stress in humans: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. (2022) 24:1047–60. doi: 10.1111/dom.14669
61
VeluthakalREsparzaDHoolachanJMBalakrishnanRAhnMOhEet al. Mitochondrial dysfunction, oxidative stress, and inter-organ miscommunications in T2D progression. Int J Mol Sci. (2024) 25:1504. doi: 10.3390/ijms25031504
62
KarunakaranUElumalaiSMoonJSWonKC. Pioglitazoneinduced AMPK-glutaminase-1 prevents high glucose-induced pancreatic β-cell dysfunction by glutathione antioxidant system. Redox Biol. (2021) 45:102029. doi: 10.1016/j.redox.2021.102029
63
MoonJSKarunakaranUElumalaiSLeeIKLeeHWKimYWet al. Metformin prevents glucotoxicity by alleviating oxidative and ER stress-induced CD36 expression in pancreatic beta cells. J Diabetes Complications. (2017) 31:21–30. doi: 10.1016/j.jdiacomp.2016.09.001
64
CaturanoARoccoMTagliaferriGPiacevoleANiloDDi LorenzoGet al. Oxidative stress and cardiovascular complications in type 2 diabetes: from pathophysiology to lifestyle modifications. Antioxidants. (2025) 14:72. doi: 10.3390/antiox14010072
65
Abdul-RahmanTRoyPAhmedFKMueller-GomezJLSarkarSGargNet al. The power of three: Retatrutide’s role in modern obesity and diabetes therapy. Eur J Pharmacol. (2024) 985:177095. doi: 10.1016/j.ejphar.2024.177095
66
SanyalAJKaplanLMFriasJPBrouwersBWuQThomasMKet al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. (2024) 30:2037–48. doi: 10.1038/s41591-024-03018-2
67
CaturanoAGalieroRLoffredoGVetranoEMedicamentoGAciernoCet al. Effects of a combination of empagliflozin plus metformin vs. Metformin monotherapy on NAFLD progression in type 2 diabetes: the IMAGIN pilot study. Biomedicines. (2023) 11:322. doi: 10.3390/biomedicines11020322
68
WangPLiuHChenLDuanYChenQXiS. Effects of a novel glucokinase activator, HMS5552, on glucose metabolism in a rat model of type 2 diabetes mellitus. J Diabetes Res. (2017) 2017:5812607. doi: 10.1155/2017/5812607
69
VellaAFreemanJLRDunnIKellerKBuseJBValcarceC. Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator. Sci Transl Med. (2019) 11:eaau3441. doi: 10.1126/scitranslmed.aau3441
70
RaoufiniaRRahimiHRSaburiEMoghbeliM. Advances and challenges of the cell-based therapies among diabetic patients. J Transl Med. (2024) 22:435. doi: 10.1186/s12967-024-05226-3
71
MaXYaoMGaoYYueYLiYZhangTet al. Functional immune cellderived exosomes engineered for the trilogy of radiotherapy sensitization. Adv Sci. (2022) 9:e2106031. doi: 10.1002/advs.202106031
72
KarBCastilloSRSabharwalAClarkKJEkkerSC. Mitochondrial base editing: recent advances towards therapeutic opportunities. Int J Mol Sci. (2023) 24:5798. doi: 10.3390/ijms24065798
73
WongMSHawthorneWJManoliosN. Gene therapy in diabetes. Self Nonself. (2010) 1:165. doi: 10.4161/self.1.3.12643
74
RakusanovaSCajkaT. Metabolomics and lipidomics for studying metabolic syndrome: insights into cardiovascular diseases, type 1 & 2 diabetes, and metabolic dysfunction-associated steatotic liver disease. Physiol Res. (2024) 73:S165–83. doi: 10.33549/physiolres.935443
75
OhSHLeeSJParkJ. Precision medicine for hypertension patients with type 2 diabetes via reinforcement learning. J Pers Med. (2022) 12:87. doi: 10.3390/jpm12010087
76
HsuNWChouKCWangYTHungCLKuoCFTsaiSY. Building a model for predicting metabolic syndrome using artificial intelligence based on an investigation of whole-genome sequencing. J Transl Med. (2022) 20:190. doi: 10.1186/s12967-022-03379-7
77
MaieseK. Diabetes mellitus and glymphatic dysfunction: Roles for oxidative stress, mitochondria, circadian rhythm, artificial intelligence, and imaging. World J Diabetes. (2025) 16:98948. doi: 10.4239/wjd.v16.i1.98948
78
TahirFFarhanM. Exploring the progress of artificial intelligence in managing type 2 diabetes mellitus: a comprehensive review of present innovations and anticipated challenges ahead. Front Clin Diabetes Healthc. (2023) 4:1316111. doi: 10.3389/fcdhc.2023.1316111
Summary
Keywords
type 2 diabetes mellitus, pathogenic mechanism, insulin resistance, mitochondrial function, obesity, gut microbiota
Citation
Wang L, Li L, Liu J, Sheng C, Yang M, Hu Z and Yue R (2025) Associated factors and principal pathophysiological mechanisms of type 2 diabetes mellitus. Front. Endocrinol. 16:1499565. doi: 10.3389/fendo.2025.1499565
Received
21 September 2024
Accepted
11 April 2025
Published
09 May 2025
Volume
16 - 2025
Edited by
Guy A. Rutter, Imperial College London, United Kingdom
Reviewed by
Maria Bayliak, Vasyl Stefanyk Precarpathian National University, Ukraine
Updates
Copyright
© 2025 Wang, Li, Liu, Sheng, Yang, Hu and Yue.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Zhipeng Hu, 2574922786@qq.com; Rensong Yue, songrenyue@cdutcm.edu.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.